Theralase Technologies (TLT) Q2 2024 earnings summary

Executive summary

• Revenue for the six-month period ended June 30, 2024, decreased 35% year-over-year, with total revenue at $276,401 compared to $426,087 in 2023.

• Gross margin declined to 33% of revenue from 47% year-over-year, attributed to increased material costs.

• Net loss narrowed by 6% to $2,400,461, primarily due to reduced research and development expenses in the Drug Division.

• Study II interim clinical data shows a 63% complete response rate, with 44% maintaining response at 12 months and no serious adverse events related to the drug or device.

Financial highlights

• Revenue dropped 35% year-over-year to $276,401, with Canadian sales down 32% and US sales down 60%.

• Gross margin fell to $90,077 (33% of revenue) from $201,140 (47% of revenue) due to higher material costs.

• Operating expenses decreased 10% to $2,490,538, with administrative expenses down 10% and Drug Division R&D down 14%.

• Device Division R&D expenses rose 225% to $81,753, reflecting new software development.

• Net loss improved 6% year-over-year to $2,400,461, with non-cash expenses totaling $374,445.

Outlook and guidance

• Plans to secure additional funding through equity and debt instruments to support Study II completion and regulatory submissions.

• Targeting completion of Study II enrollment by year-end 2024, data lock by mid-2026, and regulatory approval by end of 2026, subject to FDA Priority Review.